CXCL3 contributes to CD133+ CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Lin ^a,b   Zhang, Lixing ^a   Li, Hong ^a   Ge, Chao ^a   Zhao, Fangyu ^a   Tian, Hua ^a   Chen, Taoyang ^c   Jiang, Guoping ^d   Xie, Haiyang ^d   Cui, Ying ^e   Yao, Ming ^a   Li, Jinjun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c Qi Dong Liver Cancer Institute   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e Guangxi Cancer Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CD133 ANTIGEN; CXCL3 PROTEIN, HUMAN; PROM1 PROTEIN, HUMAN;

ANIMAL; BAGG ALBINO MOUSE; CANCER STEM CELL; CARCINOGENESIS; DOWN REGULATION; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MAPK SIGNALING; METABOLISM; MOUSE; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

AC133 ANTIGEN; ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOKINES, CXC; DOWN-REGULATION; HUMANS; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; PHOSPHORYLATION;

EID: 84973279473     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27426     Document Type: Article

References (47)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. Journal international du cancer 127, 2893-2917, doi: 10.1002/ijc.25516 (2010).
2. Singal, A. G. et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. The American journal of medicine 128, 90 e91-97, doi: 10.1016/j.amjmed.2014.07.027 (2015).
3. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi: 10.1016/j.cell.2011.02.013 (2011).
4. Ma, S. Biology and clinical implications of CD133(+ ) liver cancer stem cells. Experimental cell research 319, 126-132, doi: 10.1016/j. yexcr.2012.09.007 (2013).
5. Lee, T. K., Cheung, V. C. & Ng, I. O. Liver tumor-initiating cells as A therapeutic target for hepatocellular carcinoma. Cancer letters 338, 101-109, doi: 10.1016/j.canlet.2012.05.001 (2013).
6. Yin, S. et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. International journal of cancer. Journal international du cancer 120, 1444-1450, doi: 10.1002/ijc.22476 (2007).
7. Zhu, Z. et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. International journal of cancer. Journal international du cancer 126, 2067-2078, doi: 10.1002/ijc.24868 (2010).
8. Zhang, L. et al. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer research 72, 4276-4285, doi: 10.1158/0008-5472.CAN-12-1013 (2012).
9. Zlotnik, A. & Yoshie, O. Chemokines: A new classification system and their role in immunity. Immunity 12, 121-127 (2000).
10. Ghanem, I. et al. Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. American journal of translational research 6, 340-352 (2014).
11. Shrivastava, M. S. et al. Targeting chemokine pathways in esophageal adenocarcinoma. Cell cycle 13, 3320-3327, doi: 10.4161/15384101.2014.968426 (2014).
12. Ding, X. et al. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 16, 828-836, doi: 10.1007/s11605-011-1775-4 (2012).
13. Sutton, A. et al. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Molecular cancer therapeutics 6, 2948-2958, doi: 10.1158/1535-7163.MCT-07-0114 (2007).
14. Matsubara, T., Ono, T., Yamanoi, A., Tachibana, M. & Nagasue, N. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. Journal of surgical oncology 95, 241-249, doi: 10.1002/jso.20642 (2007).
15. Tang, L. et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene therapy 14, 1226-1234, doi: 10.1038/sj.gt.3302959 (2007).
16. Murphy, P. M. et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological reviews 52, 145-176 (2000).
17. Bieche, I. et al. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocrine-related cancer 14, 1039-1052, doi: 10.1677/erc.1.01301 (2007).
18. Engl, T. et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life sciences 78, 1784-1793, doi: 10.1016/j.lfs.2005.08.019 (2006).
19. Luan, J. et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. Journal of leukocyte biology 62, 588-597 (1997).
20. Simpson, K. J. et al. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clinical science 104, 47-63, doi: 10.1042/(2003).
21. Hooper, J. D., Baker, E., Ogbourne, S. M., Sutherland, G. R. & Antalis, T. M. Cloning of the cDNA and localization of the gene encoding human NRBP, A ubiquitously expressed, multidomain putative adapter protein. Genomics 66, 113-118, doi: 10.1006/geno.2000.6167 (2000).
22. Zhang, L. et al. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma. Oncotarget 5, 10621-10635 (2014).
23. Marotta, L. L. et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+ )CD24(-) stem cell-like breast cancer cells in human tumors. The Journal of clinical investigation 121, 2723-2735, doi: 10.1172/JCI44745 (2011).
24. Al-Alwan, L. A. et al. Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration. Journal of immunology 191, 2731-2741, doi: 10.4049/jimmunol.1203421 (2013).
25. Bishayee, A. The role of inflammation and liver cancer. Advances in experimental medicine and biology 816, 401-435, doi: 10.1007/978-3-0348-0837-8-16 (2014).
26. Airoldi, I. & Ribatti, D. Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors. Journal of leukocyte biology 90, 875-882, doi: 10.1189/jlb.0511237 (2011).
27. Sarvaiya, P. J., Guo, D., Ulasov, I., Gabikian, P. & Lesniak, M. S. Chemokines in tumor progression and metastasis. Oncotarget 4, 2171-2185 (2013).
28. Zhu, Q., Han, X., Peng, J., Qin, H. & Wang, Y. The role of CXC chemokines and their receptors in the progression and treatment of tumors. Journal of molecular histology 43, 699-713, doi: 10.1007/s10735-012-9435-x (2012).
29. Doll, D. et al. Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. International journal of colorectal disease 25, 573-581, doi: 10.1007/s00384-010-0901-1 (2010).
30. Bendall, L. Chemokines and their receptors in disease. Histology and histopathology 20, 907-926 (2005).
31. Wei, Z. W. et al. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer letters 359, 335-343, doi: 10.1016/j.canlet.2015.01.033 (2015).
32. Hustinx, S. R. et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer biology & therapy 3, 1254-1261 (2004).
33. Baird, A. M., Gray, S. G. & O'Byrne, K. J. Epigenetics underpinning the regulation of the CXC (ELR+ ) chemokines in non-small cell lung cancer. PloS one 6, e14593, doi: 10.1371/journal.pone.0014593 (2011).
34. Wurth, R., Bajetto, A., Harrison, J. K., Barbieri, F. & Florio, T. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Frontiers in cellular neuroscience 8, 144, doi: 10.3389/fncel.2014.00144 (2014).
35. Uemae, Y. et al. CXCL12 secreted from glioma stem cells regulates their proliferation. Journal of neuro-oncology 117, 43-51, doi: 10.1007/s11060-014-1364-y (2014).
36. Gil, M. et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. Journal of immunology 193, 5327-5337, doi: 10.4049/jimmunol.1400201 (2014).
37. Yu, Z. H., Liu, T., Zhao, Y. H., Huang, Y. Y. & Gao, Y. T. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35, 4637-4644, doi: 10.1007/s13277-014-1607-8 (2014).
38. Kogan-Sakin, I. et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis 30, 698-705, doi: 10.1093/carcin/bgp043 (2009).
39. Schwickert, T. A. et al. Stage-specific control of early B cell development by the transcription factor Ikaros. Nature immunology 15, 283-293, doi: 10.1038/ni.2828 (2014).
40. Jager, R. et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24, 1290-1298, doi: 10.1038/leu.2010.99 (2010).
41. Bourseau-Guilmain, E., Griveau, A., Benoit, J. P. & Garcion, E. The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PloS one 6, e25515, doi: 10.1371/journal. pone.0025515 (2011).
42. Shimozato, O. et al. Receptor-type protein tyrosine phosphatase kappa directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene, doi: 10.1038/onc.2014.141 (2014).
43. Liu, Z., Yang, L., Xu, J., Zhang, X. & Wang, B. Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. The Journal of surgical research 166, 241-246, doi: 10.1016/j.jss.2009.07.014 (2011).
44. Tang, K. H. et al. CD133(+ ) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55, 807-820, doi: 10.1002/hep.24739 (2012).
45. Wang, Y. K. et al. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 31, 1376-1380, doi: 10.1093/carcin/bgq120 (2010).
46. Rohani, M. G. et al. PAR1-and PAR2-induced innate immune markers are negatively regulated by PI3K/Akt signaling pathway in oral keratinocytes. BMC immunology 11, 53, doi: 10.1186/1471-2172-11-53 (2010).
47. Bandow, K. et al. LPS-induced chemokine expression in both MyD88-dependent and-independent manners is regulated by Cot/Tpl2-ERK axis in macrophages. FEBS letters 586, 1540-1546, doi: 10.1016/j.febslet.2012.04.018 (2012).